Physician
Oncology
Roscoe F. Morton works in the field of Oncology. He researched medicine at University of Kansas School of Medicine. He has 11 awards "Fellow", "Member, Nominating Committee", "Chair, Clinical Practice Committee", "Member, Government Relations Committee", "Member, GI Steering Committee", "Member, Ethics Committee", "Chair, Executive Committee", "Clinical Fellow", "Alpha Omega Alpha", "CMS Meaningful Use Stage 1 Certification" and "Member". Roscoe Morton is a published physician. He published 26 publications, including: 'ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.' Doctor Roscoe F. Morton, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
- Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal Cancer: results from North American Gastrointestinal Intergroup Tria...
- NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic coloRectal carcinoma to predict respons...
- ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.
- Phase II trial of sorafenib in patients with metastatic breast Cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Cl...
- Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study...
- Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal Cancer: N9741.
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group...
- A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Long-term results of the treatment of patients with mantle Cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central C...
- Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal Cancer.
- Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with ...
- Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon Cancer.
- Low-molecular-weight heparin in patients with advanced Cancer: a phase 3 clinical trial.
- Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle Cell lymphoma.
- Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal Cancer.
- Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
- Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
- A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic coloRectal can...
- Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small Cell lung carcinoma: a phase II ...
- Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.
- Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity mon...
- A phase II trial of docetaxel and CPT-11 in patients with metastatic adenoCarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Schools
University of Kansas School of Medicine
University Kans Affil Hosps
Mayo Grad School
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow
- Member, Nominating Committee
- Chair, Clinical Practice Committee
- Member, Government Relations Committee
- Member, GI Steering Committee
- Member, Ethics Committee
- Chair, Executive Committee
- Clinical Fellow
- Alpha Omega Alpha
- CMS Meaningful Use Stage 1 Certification
- Member
Education
-
Mayo School of Graduate Medical Education
-
University of Kansas at Wichita
-
University of Kansas School of Medicine
Hospital
-
UnityPoint Health - Iowa Methodist Medical Center
Drug Facts
| NPI NUMBER |
|
1447215629 |
| NPPES Provider LastName |
|
MORTON |
| NPPES Provider FirstName |
|
ROSCOE |
| NPPES Provider ZIPCode |
|
50309 |
| NPPES Provider State |
|
IA |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
1348.0 |
| Distinct Opioid Count |
|
5.0 |
| Opioid Claim Count |
|
167.0 |
| Percent Opioid Claims |
|
12.39 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1447215629 |
| Last Name Of The Provider |
MORTON |
| First Name Of The Provider |
ROSCOE |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
